Open Access<p>New Benzofuran <em>N</em>-Acylhydrazone Reduces Cardiovascular Dysfunction in Obese Rats by Blocking TNF-Alpha Synthesis</p>
Author(s) -
Gizele Cabral Costa,
Tadeu L. Montagnoli,
Jaqueline Soares Da Silva,
Alexandre Alencar,
Luis Eduardo Reina Gamba,
Bryelle Eccard,
Marina Moraes Carvalho da Silva,
Margarete M. Trachez,
José Nascimento,
Pedro M. PimentelCoelho,
Rosália Mendez-Otero,
Lı́dia Moreira Lima,
Eliezer J. Barreiro,
Roberto T. Sudo,
Gisele ZapataSudo
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s258459
Subject(s) - medicine , endocrinology , diabetic cardiomyopathy , ventricle , diabetes mellitus , metabolic syndrome , type 2 diabetes , cardiac function curve , cardiomyopathy , heart failure
Diabetic obese patients are susceptible to the development of cardiovascular disease, including hypertension and cardiac dysfunction culminating in diabetic cardiomyopathy (DC), which represents a life-threatening health problem with increased rates of morbidity and mortality. The aim of the study is to characterize the effects of a new benzofuran N -acylhydrazone compound, LASSBio-2090, on metabolic and cardiovascular alterations in Zucker diabetic fatty (ZDF) rats presenting DC.